DV
Dividend Vision

TLX — Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (TLX)

Total return is -22.0% over the past 1.7 years, 55.5 points behind SPY at 33.5%. Its deepest 1-year drawdown was 48.9%.

Telix Pharmaceuticals Limited is an individual pharmaceutical stock rather than a diversified ETF, focused on the development and commercialization of diagnostic and therapeutic radiopharmaceutical products. As a single-stock holding with no dividend distribution history, it generates no yield and carries the concentration risk typical of direct equity positions rather than the diversification benefits of a traditional fund structure. This holding appeals primarily to growth-oriented investors seeking exposure to the biotechnology and radiopharmaceutical sector, rather than those pursuing dividend income.

TLX key facts

Asset type
Stock
Asset class
Equity
Inception date
11/14/2024
Last close
$11.82
Market cap
$3,560,546,816
Average volume
120675.0
Beta
0.631
Payout ratio
0.0
Forward P/E
2000.0
EPS
$-0.02